---
layout: default
title: Escitalopram
parent: 僅模型預測 (L5)
nav_order: 129
evidence_level: L5
indication_count: 0
---

# Escitalopram
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Escitalopram: Drug Repurposing Evaluation — Insufficient Data for TxGNN Prediction

## One-Sentence Summary

Escitalopram is a selective serotonin reuptake inhibitor (SSRI) clinically established for major depressive disorder and generalised anxiety disorder.
The TxGNN prediction pipeline returned **no predicted new indications** for this candidate, as critical input data — including original indications, mechanism of action, and local regulatory records — are absent from the Evidence Pack.
This report documents all identified data gaps and defines the remediation steps required before a formal repurposing analysis can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in Evidence Pack *(Escitalopram is clinically used for major depressive disorder and generalised anxiety disorder)* |
| Predicted New Indication | **None** — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | **L5** — Pipeline incomplete; no actual study evidence assessed |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The `predicted_indications` array in the Evidence Pack is empty, meaning the TxGNN prediction pipeline did not produce output for this drug. This typically occurs when the drug profile lacks the minimum required fields — specifically original approved indications and a DrugBank-mapped identifier — needed to anchor the drug within the knowledge graph.

Detailed mechanism of action data is not available in this Evidence Pack. Based on publicly known pharmacology, Escitalopram (DrugBank DB01175) is the S-enantiomer of citalopram and the most selective member of the SSRI class. It inhibits the serotonin transporter (SERT), thereby increasing synaptic serotonin concentration. This mechanism has been hypothesised to have relevance beyond depression — including in neuropathic pain, irritable bowel syndrome, and certain inflammatory conditions — but none of these potential new indications can be formally scored or ranked without completing the prediction run.

Until the data pipeline is re-run with a complete drug profile, no mechanistic applicability assessment can be made and no evidence tables can be generated.

---

## Safety Considerations

Please refer to the package insert for safety information.

> ⚠️ **Data Gap DG001 (Blocking):** Package insert warnings and contraindications have not been retrieved. This gap blocks the safety screening stage (S1). Remediation: download the official package insert PDF from the local regulatory authority and parse the relevant sections.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is critically incomplete on multiple dimensions — no TxGNN predictions were generated, original indications are absent, mechanism of action is missing, and no local regulatory or safety data is on record. A repurposing evaluation cannot be meaningfully conducted in this state.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Retrieve the official package insert from the relevant regulatory authority; extract approved indications, warnings, and contraindications.
- **[High — DG002]** Query DrugBank API for DB01175 to populate mechanism of action, drug categories, and pharmacodynamic data.
- **[Required]** Re-run the TxGNN prediction pipeline with a complete drug profile (original indications + MOA + regulatory status) to generate `predicted_indications`.
- **[Recommended]** Confirm Philippines FDA registration status via the online product verification portal; if unregistered, assess importation or registration pathway before any clinical translation.
- **[Next step after pipeline completion]** Reassign evidence level (L1–L5), generate clinical trial and literature evidence tables, and re-score this candidate for a full Go / Proceed with Guardrails decision.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

